Evaluate the Safety and Tolerability of CE211NS21 in Patients With AQP4-IgG-positive NMOSD Relapse

Phase 1 Not yet recruiting 6 enrolled Corestemchemon, Inc.

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and tolerability of allogeneic bone marrow-derived mesenchymal stem cells (CE211NS21) in patients with severe anti-aquaporin-4-immunoglobulin G positive neuromyelitis optica spectrum disorder (AQP4-IgG-positive NMOSD) relapse

Timeline

Start: 2026-12-01
Primary completion: 2027-12-30
Completion: 2028-12-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CE211NS21	Cell therapy	1e+06 cells/kg	Intrathecal
Subject	CE211NS21	Cell therapy	2e+06 cells/kg	Intrathecal

Evaluate the Safety and Tolerability of CE211NS21 in Patients With AQP4-IgG-positive NMOSD Relapse

Summary

Timeline

Drugs

Indications